Expertise in
6
conditions

Dr. Joel Schlessinger

Dermatology
Skin Specialists P C
2802 Oak View Dr, 
Omaha, NE 
 (802.1 mi)
Accepting New Patients
Expertise in
6
conditions
Skin Specialists P C
2802 Oak View Dr, 
Omaha, NE 
 (802.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

Joel Schlessinger is a Dermatologist in Omaha, Nebraska. Dr. Schlessinger is highly rated in 6 conditions, according to our data. His top areas of expertise are Impetigo, Rosacea, Kerion Celsi, and Ringworm. Dr. Schlessinger is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in NE
Hospital Affiliations
The Nebraska Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Wellmark
  •  Medica
  •  Blue Cross Blue Shield
  •  Oscar
  •  Humana

Locations

SKIN SPECIALISTS P C
2802 Oak View Dr, Omaha, NE 68144

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: August 18, 2020
Intervention Type: Drug
Study Phase: Phase 3
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Enrollment Status: Completed
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
Enrollment Status: Completed
Publish Date: October 20, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

45 Total Publications

A Review of Current Data on Duration of Effect in Glabellar Lines After Treatment With AbobotulinumtoxinA 50 U.
A Review of Current Data on Duration of Effect in Glabellar Lines After Treatment With AbobotulinumtoxinA 50 U.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: August 28, 2024
Similar Doctors
Expertise in
34
conditions
Dr. Jason S. Papenfuss
Dermatology
Expertise in
34
conditions
Dr. Jason S. Papenfuss
Dermatology

Midwest Dermatology Clinic, P.C.

2323 S 171st St, Suite 100, 
Omaha, NE 
 (2.6 mi)
402-933-0800
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jason Papenfuss is a Dermatologist in Omaha, Nebraska. Dr. Papenfuss is highly rated in 34 conditions, according to our data. His top areas of expertise are Seborrheic Keratosis, Syringoma, Syringocystadenoma Papilliferum, and Sebaceous Adenoma. Dr. Papenfuss is currently accepting new patients.

Expertise in
32
conditions
Dr. James M. Shehan
Dermatology
Expertise in
32
conditions
Dr. James M. Shehan
Dermatology

Advanced Dermatology Of The Midlands PC

15805 W Maple Rd, Suite 104, 
Omaha, NE 
 (4.3 mi)
402-933-3770
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Shehan is a Dermatologist in Omaha, Nebraska. Dr. Shehan is highly rated in 32 conditions, according to our data. His top areas of expertise are Sunburn, Basal Cell Skin Cancer, Bullous Pemphigoid, and Actinic Keratosis. Dr. Shehan is currently accepting new patients.

Expertise in
3
conditions
Dr. Madison L. Grinnell
Dermatology
Expertise in
3
conditions
Dr. Madison L. Grinnell
Dermatology
Lauritzen Outpatient Center, 4014 Leavenworth St, 
Omaha, NE 
 (8.9 mi)
800-922-0000
Languages Spoken:
English

Madison Grinnell is a Dermatologist in Omaha, Nebraska. Dr. Grinnell is highly rated in 3 conditions, according to our data. Her top areas of expertise are Dermatomyositis, Cutaneous Lupus Erythematosus (CLE), Discoid Lupus Erythematosus (DLE), and Livedo Reticularis.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile